arrow
J

Jiacheng Dai

Central South University
H指数:4
被引数:53

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial

安罗替尼联合派安普利在二线治疗小细胞肺癌中的疗效及生物标志物探索:ALTER-L041期2临床试验结果

2026-07-220
OAAI
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial

非小细胞肺癌的日间免疫化疗: 一项随机3期试验

2026-02-020
PRE
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

PD-1/PD-L1双特异性抗体IBI318联合仑伐替尼治疗对免疫检查点抑制剂获得性耐药的晚期非小细胞肺癌:一项II期临床试验

2025-12-150
OAAI
Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) project
2024-03-254
OAAI